Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.
作者信息
Simone Tessa M, Higgins Paul J
机构信息
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York 12208.
出版信息
New Horiz Transl Med. 2014 Sep 1;2(1):16-19. doi: 10.1016/j.nhtm.2014.08.003.
Abstract
摘要
相似文献
1
Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.
New Horiz Transl Med. 2014 Sep 1;2(1):16-19. doi: 10.1016/j.nhtm.2014.08.003.
2
Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2167-2175. doi: 10.1161/ATVBAHA.116.308344. Epub 2016 Sep 22.
3
Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury.
Adv Wound Care (New Rochelle). 2015 Jun 1;4(6):321-328. doi: 10.1089/wound.2014.0611.
4
The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2.
Exp Cell Res. 2015 Mar 15;332(2):278-87. doi: 10.1016/j.yexcr.2015.02.006. Epub 2015 Feb 19.
5
Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
J Cell Physiol. 2005 Jul;204(1):236-46. doi: 10.1002/jcp.20279.
6
Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1.
J Cell Biochem. 2004 May 1;92(1):178-88. doi: 10.1002/jcb.20058.
7
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.
J Cell Biol. 1998 Jan 12;140(1):233-45. doi: 10.1083/jcb.140.1.233.
8
Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes.
Coron Artery Dis. 1998;9(4):177-84. doi: 10.1097/00019501-199809040-00002.
9
Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension.
Int J Biochem Cell Biol. 2008;40(9):1872-82. doi: 10.1016/j.biocel.2008.01.028. Epub 2008 Feb 2.
10
Immunoelectron microscopic localization of plasminogen activator inhibitor type 1 (PAI-1) in smooth muscle cells from morphologically normal and atherosclerotic human arteries.
Ultrastruct Pathol. 1997 Nov-Dec;21(6):527-36. doi: 10.3109/01913129709016369.
本文引用的文献
1
A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma.
Am J Respir Cell Mol Biol. 2012 Jun;46(6):842-6. doi: 10.1165/rcmb.2011-0369OC. Epub 2012 Feb 9.
2
Ligation of macrophage Fcγ receptors recapitulates the gene expression pattern of vulnerable human carotid plaques.
PLoS One. 2011;6(7):e21803. doi: 10.1371/journal.pone.0021803. Epub 2011 Jul 21.
3
Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice.
Diabetes. 2011 Jul;60(7):1964-72. doi: 10.2337/db11-0007. Epub 2011 May 18.
4
TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.
Cardiovasc Res. 2011 Jan 1;89(1):225-33. doi: 10.1093/cvr/cvq278. Epub 2010 Sep 1.
5
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.
J Biol Chem. 2009 Dec 18;284(51):35906-15. doi: 10.1074/jbc.M109.072256.
6
The 'PAI-1 paradox' in vascular remodeling.
Thromb Haemost. 2008 Dec;100(6):984-91.
7
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
Cancer Cell. 2008 Oct 7;14(4):324-34. doi: 10.1016/j.ccr.2008.08.012.
8
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.
J Biol Chem. 2007 Mar 23;282(12):9288-96. doi: 10.1074/jbc.M611642200. Epub 2007 Feb 2.
9
Tiplaxtinin impairs nutritionally induced obesity in mice.
Thromb Haemost. 2006 Dec;96(6):731-7.
10
PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy.
Thromb Haemost. 2006 Dec;96(6):698-9.
Zotero 插件